Oncodesign and Banook Central Imaging Sign a Collaboration Agreement
News Sep 10, 2013
Oncodesign and Banook Central Imaging have announced the start of a partnership to expand the use of new approaches in pharmaco-imaging.
The partners expect to share expertise, co-promote joint activities and jointly engage in scientific collaboration to standardize image acquisition and analysis protocols in early clinical phases.
The financial details of the agreement were not disclosed.
The various medical imaging procedures (computed tomography, magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography and ultrasound imaging) have become indispensable tools in early-stage development of anticancer compounds.
The information they provide about the disease and the effects of molecules is highly valuable in identifying translational markers in preclinical and clinical phases.
The partnership between Oncodesign and Banook Central Imaging breaks new ground in the evaluation of anticancer therapies by helping to guide a compound from research laboratory to patient through the pursuit of greater consistency in the imaging protocols used during the development cycle, in accordance with good clinical practice.
The first phase of this partnership will last three years. First results are expected by early 2014.
“Oncodesign leads the way in pharmaco-imaging. As well as conducting preclinical proofs of concept, we have a long tradition of striving to provide our clients with tools for improving the characterization of their molecule's therapeutic potential, to expedite clinical trials in humans,” said Philippe Genne, PhD, CEO and founder of Oncodesign.
Genne continued, “In the coming weeks, our partnership with Banook Central Imaging will help us to provide our clients with practical solutions, ensuring that the measure of efficacy of anticancer therapies is attainable from one phase of development to the next.”
“It is crucial that the challenges of standardizing biomarkers in pharmaco-imaging are considered from the early phases of clinical development,” said Dr Pascal Voiriot, MSc, chairman of Banook Central Imaging.
Dr Voiriot continued, “Our partnership with Oncodesign is in line with our strategy which aims to implement relevant biomarkers in medical imaging, focusing ultimately on personalized medicine and the ability to produce a considerable time saving for the direct benefit of research laboratories and patients.”
A joint announcement about the partnership will be made at the ESMO (European Society for Medical Oncology) conference to be held in Amsterdam, the Netherlands, from September 27 to October 1.
Cryo-EM Reveals Interaction Between Major Drug TargetsNews
For the first time, scientists have visualized the interaction between two critical components of the body's vast cellular communication network, a discovery that could lead to more effective medications with fewer side effects for conditions ranging from migraine to cancer.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE